0001818331-25-000130
SEC filingRevenue rose 52% YoY to $116.7M, driven by 65% exome/genome revenue growth, while gross margin expanded 1,020 bps to 72.4%.
For the three months ended September 30, 2025, total revenue increased 52% to $116.7 million from $76.9 million in the same period last year. Diagnostic test revenue rose 47% to $113.5 million, driven by a 65% surge in whole exome and genome sequencing revenues, underpinned by a 33% increase in test volumes and higher average reimbursement rates. Other revenue climbed $3.8 million to $3.2 million, benefiting from the Fabric Genomics acquisition ($1.7 million) and expanded biopharma collaborations, partially offset by a negative prior-year adjustment. Gross profit improved 77% to $84.5 million, with gross margin expanding 1,020 basis points to 72.4% from 62.2%, reflecting a favorable shift in test mix toward higher-margin exome/genome tests and continued cost per test leverage. Operating expenses rose: R&D increased 70% to $19.8 million (driven by product development investment and Fabric Genomics), selling and marketing rose 38% to $23.5 million, and G&A increased 65% to $44.4 million (compensation, legal, IT). Despite higher expenses, the operating loss narrowed 58% to $3.3 million. Non-operating expense net widened to $4.1 million due to a $3.4 million loss from fair value changes of contingent consideration. Net loss improved 8% to $7.6 million. On an adjusted basis (excluding depreciation, stock comp, restructuring, fair value changes, and certain items), net income was $14.7 million versus $2.0 million in the prior year.
For the nine months, total revenue rose 46% to $306.6 million, with diagnostic revenue up 44% to $299.4 million, driven by 66% growth in exome/genome revenues on 29% volume growth and 29% higher average reimbursement. Gross margin improved 870 bps to 69.8%. Operating income turned positive at $1.2 million versus a $32.0 million loss. Net loss narrowed 94% to $3.4 million. Adjusted net income was $37.4 million versus a $8.0 million adjusted loss.
The company reports two revenue streams: Diagnostic Testing and Other Revenue. Diagnostic testing is the primary segment, contributing 97% of total revenue in Q3 2025. Within diagnostics, the mix shift toward exome and genome tests is pronounced—these tests represented 43% of all test results in Q3 2025, up from 33% a year ago. The growth in exome/genome volumes (33% increase) and reimbursement rates (driving 65% revenue growth) indicate successful commercial execution and improved payer coverage. The non-exome test revenues declined, partly offsetting the gains. Other revenue, while smaller, is growing rapidly due to the Fabric Genomics acquisition and data program expansion. The MD&A does not provide segment-level profitability, but the overall gross margin improvement is attributed solely to diagnostics.
The MD&A does not provide explicit quantitative guidance for future periods. However, management outlines several strategic priorities: continuing to increase exome/genome test adoption, expanding reimbursement coverage, lowering cost per test through automation and value engineering, and investing in platform innovation. The company expects operating expenses to increase in absolute dollars but decline as a percentage of revenue over the long term. Liquidity remains sufficient for at least 12 months with $155.1 million in cash and marketable securities. Notable contractual obligation: $12.0 million remaining settlement payments to a third-party payor, with $10.0 million due before year-end 2025. The company plans to file a new automatic shelf registration statement after the prior one expired. No seasonality or specific forward milestones were discussed.
As of September 30, 2025, GeneDx held $95.968M in cash and cash equivalents plus $59.111M in marketable securities, totaling $155.079M in liquid assets. The company's total debt stood at $54.847M gross ($51.579M net of issuance costs), consisting of a $50.0M Perceptive Term Loan due 2028 and a $4.8M DECD loan due 2029. No significant debt maturities until 2028, with interest-only payments on the term loan. Stockholders' equity improved to $292.258M from $245.247M at year-end 2024, driven by a $25.6M ATM offering and $22.4M in stock-based compensation, partially offset by a net loss of $3.355M. Goodwill increased to $12.798M from nil, reflecting the Fabric Genomics acquisition.
Total purchase commitments were $31.739M as of September 30, 2025, primarily for software and equipment. Obligations by period: $3.131M in the remainder of 2025, $13.036M in 2026, $6.641M in 2027, $4.039M in 2028, $3.914M in 2029, and $0.978M thereafter. The company also has operating lease obligations (not material change from prior year) and a contingent consideration liability of $6.810M related to the Fabric Genomics acquisition, which may require cash or stock payments in 2026 and 2027 if performance milestones are met.
GeneDx did not repurchase shares or pay dividends during the period. The company raised $25.6M net from an ATM offering completed in Q3 2025. Capital expenditures totaled $14.670M for the nine months, funded by operating cash flow of $36.369M. Debt reduction was minimal ($0.9M in DECD principal payments). The Perceptive loan remains outstanding with no scheduled amortization; prepayment would incur a premium of up to 10%.
The company operates through one reportable segment, GeneDx, which accounted for 98% of total revenue in Q3 2025 ($114.7M vs. $2.0M from Other). GeneDx revenue grew 50% YoY, driven by higher diagnostic test volumes and favorable payor mix. The Other segment includes Fabric Genomics (acquired May 2025) and the winding-down Legacy Sema4. Adjusted gross profit margin for GeneDx was 73.6% (84.451 / 114.697), up from 64.3% in Q3 2024, reflecting improved revenue quality and cost leverage. No geographic breakdown was provided.
The Notes also disclose that $1.0M of revenue in Q3 2025 came from favorable prior-period adjustments related to variable consideration reassessment, and third-party payor reserves increased to $21.3M.
For the nine months ended September 30, 2025, GeneDx generated $36.4M in operating cash flow, a significant improvement from a $(25.3)M use in the prior year. The net loss narrowed from $(57.7)M to $(3.4)M, driven by higher non-cash charges (stock-based compensation up to $22.4M from $6.3M) and a $8.7M increase in third-party payor reserves. Working capital changes consumed $15.9M, primarily from an accounts receivable increase of $22.8M, partially offset by a $5.2M increase in payables.
Capital expenditures (capex) rose sharply to $14.7M from $2.4M, reflecting investments in property and equipment. Investing activities also included a $33.2M cash outflow for the acquisition of Fabric Genomics and net purchases of marketable securities. Financing activities provided $24.8M, mainly from stock offerings ($25.6M). The company ended the period with $97.0M in cash, cash equivalents, and restricted cash, up from $86.2M at the start. Despite positive operating cash flow, the heavy investing outflows resulted in a net cash increase of only $10.8M. Free cash flow was not explicitly stated but can be approximated as operating cash flow minus capec, which would be $21.7M, though this ignores the acquisition and other investing items.